What therapeutic measure is often prescribed to reduce airway inflammation in a patient with chronic asthma?

A. Antibiotics: These agents are pharmacological substances designed to eradicate or inhibit the growth of pathogenic bacteria during an active infection. While asthma may be exacerbated by respiratory infections, antibiotics do not possess the anti-inflammatory properties required to manage chronic bronchial hyperreactivity. They do not address the underlying eosinophilic or lymphocytic infiltration of the airway. B. Beta-agonists: These medications act on beta-2 adrenergic receptors to induce smooth muscle relaxation and rapid bronchodilation during acute bronchospasm. While essential for relieving immediate obstructive symptoms, they do not inhibit the underlying inflammatory cascade or reduce mucosal edema. Excessive use without anti-inflammatory coverage can lead to receptor downregulation and poor asthma control. C. Antihistamines: These drugs antagonize H1 receptors to mitigate the effects of histamine release during Type 1 hypersensitivity reactions, primarily affecting the upper respiratory tract. Although they may assist in managing comorbid allergic rhinitis, they are not effective for the primary management of lower airway inflammation. They lack the potency to suppress the complex cellular inflammation of asthma. D. Corticosteroids: These potent anti-inflammatory agents inhibit the production of inflammatory mediators, such as cytokines and leukotrienes, while reducing the migration of eosinophils. By suppressing the immune response within the bronchial mucosa, they reduce airway edema and hyperresponsiveness over time. They represent the gold standard for long-term maintenance therapy in chronic asthma.